Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

NEW YORK – The US Food and Drug Administration announced Thursday that Cepheid's test for SARS-CoV-2, influenza, and respiratory syncytial virus received Emergency Use Authorization for use in high and moderate complexity laboratories and at the point of care. 

The rapid multiplex RT-PCR test detects and differentiates SARS-CoV-2, influenza A and B, and respiratory syncytial virus RNA and can provide results in 35 minutes. 

The test runs on the company's GeneXpert Dx and GeneXpert Infinity instruments in CLIA-certified moderate and high complexity labs and is indicated for use with nasopharyngeal and nasal swabs and nasal wash/aspirate specimens. The Xpert Xpress SARS-CoV-2/Flu/RSV test runs on the GeneXpert Xpress System at the point of care and is authorized for nasopharyngeal and nasal swabs in CLIA-waived settings.

The Danaher subsidiary announced plans to launch the multiplex test during its second quarter earnings call in July. Cepheid was the first company to receive EUA for a point-of-care test for SARS-CoV-2 in March.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.